| 2314- | Api, | Apigenin Restrains Colon Cancer Cell Proliferation via Targeted Blocking of Pyruvate Kinase M2-Dependent Glycolysis |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 | - | in-vitro, | Colon, | DLD1 |
| 1095- | Api, | Apigenin inhibits epithelial-mesenchymal transition of human colon cancer cells through NF-κB/Snail signaling pathway |
| - | Analysis, | Colon, | NA |
| 1077- | Api, | Apigenin inhibits COX-2, PGE2, and EP1 and also initiates terminal differentiation in the epidermis of tumor bearing mice |
| - | in-vivo, | NMSC, | NA |
| 1008- | Api, | Apigenin-induced lysosomal degradation of β-catenin in Wnt/β-catenin signaling |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 1024- | Api, | CUR, | Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects |
| - | vitro+vivo, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 | - | in-vitro, | Melanoma, | RPMI-7951 |
| 581- | Api, | Cisplatin, | The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy |
| - | in-vitro, | Pca, | CD44+ |
| 577- | Api, | PacT, | Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 578- | Api, | Cisplatin, | Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Pca, | HeLa | - | in-vitro, | Lung, | H1299 |
| 583- | Api, | Cisplatin, | Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study |
| - | in-vitro, | Laryn, | HEp2 |
| 584- | Api, | Cisplatin, | Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms |
| - | in-vivo, | Var, | NA |
| 586- | Api, | 5-FU, | 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 589- | Api, | 5-FU, | Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro |
| - | in-vitro, | PC, | Bxpc-3 |
| 591- | Api, | doxoR, | Polyphenols act synergistically with doxorubicin and etoposide in leukaemia cell lines |
| - | in-vitro, | AML, | Jurkat | - | in-vitro, | AML, | THP1 |
| 5- | Api, | Common Botanical Compounds Inhibit the Hedgehog Signaling Pathway in Prostate Cancer |
| - | in-vitro, | Pca, | NA |
| 958- | Api, | Apigenin suppresses tumor angiogenesis and growth via inhibiting HIF-1α expression in non-small cell lung carcinoma |
| - | in-vitro, | Lung, | NCIH1299 |
| 938- | Api, | doxoR, | Apigenin and hesperidin augment the toxic effect of doxorubicin against HepG2 cells |
| - | vitro+vivo, | HCC, | HepG2 |
| 983- | Api, | Apigenin acts as a partial agonist action at estrogen receptors in vivo |
| - | in-vivo, | NA, | NA |
| 177- | Api, | Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21WAF1/CIP1 expression |
| - | in-vitro, | BC, | MDA-MB-231 |
| 307- | Api, | Flavonoids inhibit angiogenic cytokine production by human glioma cells |
| - | in-vitro, | GBM, | GL-15 |
| 311- | Api, | Apigenin inhibits the proliferation of adenoid cystic carcinoma via suppression of glucose transporter-1 |
| - | in-vitro, | ACC, | NA |
| 310- | Api, | Apigenin inhibits renal cell carcinoma cell proliferation |
| - | vitro+vivo, | RCC, | ACHN | - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | Caki-1 | - | in-vitro, | RCC, | HK-2 |
| - | in-vitro, | BC, | BT474 |
| 313- | Api, | Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells |
| - | in-vitro, | Thyroid, | BCPAP |
| 314- | Api, | Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis |
| - | in-vitro, | SCC, | HaCaT | - | in-vitro, | SCC, | SCC25 |
| 308- | Api, | Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U373MG |
| 243- | Api, | Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 |
| 315- | Api, | Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer |
| - | vitro+vivo, | PC, | Panc02 |
| 178- | Api, | Autophagy inhibition enhances apigenin-induced apoptosis in human breast cancer cells |
| - | in-vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | T47D |
| 179- | Api, | Apigenin induces caspase-dependent apoptosis by inhibiting signal transducer and activator of transcription 3 signaling in HER2-overexpressing SKBR3 breast cancer cells |
| - | in-vitro, | BC, | SkBr3 |
| 180- | Api, | Induction of caspase-dependent apoptosis by apigenin by inhibiting STAT3 signaling in HER2-overexpressing MDA-MB-453 breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 206- | Api, | Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | A549 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Lung, | H2030 | - | in-vitro, | CRC, | SW480 |
| 207- | Api, | Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells |
| - | in-vitro, | Pca, | LNCaP |
| 208- | Api, | Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70–Bax interaction in prostate cancer |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | DU145 |
| 210- | Api, | Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer |
| - | in-vitro, | Pca, | DU145 |
| 211- | Api, | Suppression of NF-κB and NF-κB-Regulated Gene Expression by Apigenin through IκBα and IKK Pathway in TRAMP Mice |
| - | in-vivo, | Pca, | NA |
| 171- | Api, | Apigenin in cancer therapy: anti-cancer effects and mechanisms of action |
| - | Review, | Var, | NA |
| 275- | Api, | Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells |
| - | in-vitro, | Ovarian, | SKOV3 |
| 273- | Api, | Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase |
| - | in-vivo, | Ovarian, | A2780S |
| 270- | Api, | Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo via inactivation of Akt and activation of JNK |
| - | in-vivo, | AML, | U937 |
| 269- | Api, | Cytotoxicity of apigenin on leukemia cell lines: implications for prevention and therapy |
| - | in-vitro, | AML, | HL-60 | - | in-vitro, | AML, | K562 | - | in-vitro, | AML, | TF1 |
| 268- | Api, | Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells |
| - | in-vitro, | AML, | HL-60 |
| 175- | Api, | Apigenin up-regulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT |
| - | vitro+vivo, | CRC, | SW480 | - | vitro+vivo, | CRC, | DLD1 | - | vitro+vivo, | CRC, | LS174T |
| 172- | Api, | Apigenin suppresses colorectal cancer cell proliferation, migration and invasion via inhibition of the Wnt/β-catenin signaling pathway |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | HTC15 |
| 173- | Api, | Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells |
| - | in-vitro, | Colon, | HCT116 |
| 244- | Api, | Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma |
| - | in-vivo, | Melanoma, | B16-F10 | - | in-vivo, | Melanoma, | A375 | - | in-vivo, | Melanoma, | G361 |
| 174- | Api, | Downregulation of NEDD9 by apigenin suppresses migration, invasion, and metastasis of colorectal cancer cells |
| - | in-vitro, | CRC, | SW480 | - | in-vitro, | CRC, | DLD1 |
| 242- | Api, | Apigenin inhibits proliferation and invasion, and induces apoptosis and cell cycle arrest in human melanoma cells |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | C8161 |
| 240- | Api, | The flavonoid apigenin reduces prostate cancer CD44(+) stem cell survival and migration through PI3K/Akt/NF-κB signaling |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | CD44+ |
| 238- | Api, | Apigenin inhibits TGF-β-induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | C4-2B |
| 237- | Api, | Apigenin blocks IKKα activation and suppresses prostate cancer progression |
| - | in-vivo, | Pca, | PC3 | - | in-vivo, | Pca, | 22Rv1 | - | in-vivo, | Pca, | LNCaP | - | in-vivo, | Pca, | DU145 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid